AN2 TherapeuticsANTX
Recorded

AN2 Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration23 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hi, everyone. Good morning. Welcome to the 2026 Jefferies Healthcare Conference. It's my pleasure to welcome Eric Easom, CEO of AN2 Therapeutics.

Eric EasomCEO

Thank you. All right. Thank you very much.

Eric EasomCEO

I'll be making certain forward-looking statements, so I wanted to make sure that that was known. To introduce AN2 Therapeutics. We are a boron chemistry platform-based company, and we have a strong clinical pipeline with three clinical proof of concept studies that are either ongoing or very close to starting in the next few weeks. We've got three of those. Our lead program is in hematology for polycythemia vera, or PV. I'll talk a lot more about that in this session. We also have two other projects for NTM, nontuberculous mycobacteria lung disease, targeting Mycobacterium abscessus, as well as Chagas disease. These are all proof of concept. They're novel. Two of these indications have no FDA-approved drugs, so we're very excited about the potential of these to help patients.

Eric EasomCEO

Near-term catalyst, we've got a very catalyst-rich 2027, and we've got all three of these will be reading out. Nearest term will be the polycythemia vera trial, and that we'll see starting as soon as the first quarter and throughout 2027. We also have a robust research pipeline, or R&D pipeline, that has a couple of development compounds that we've recently announced in oncology for ENPP1, and then most recently for hypophosphatasia, oral ENPP1 inhibitor that we're also excited. We've got a lot going on and a very productive boron platform here. Just to look at it in kind of a traditional pipeline sense. This shows the three lead compounds, but the main point I wanted to make here is that we're a platform company, and we follow biology. We've really expanded our focus from originally we were more focused on infectious diseases.

Eric EasomCEO

Now we have a very robust hematology and oncology pipeline with a very unique chemistry approach to it. We've got a strong infectious diseases pipeline with products that address high unmet needs and also have high commercial potential. Recently, as I mentioned, we have a rare bone disorder project in hypophosphatasia that we're very excited about. Something that's near and dear to us as a company that kind of sets us uniquely apart is we've been involved in global health from our earlier Anacor days up to AN2, and so we have a number of projects there. We've discovered probably 15 compounds for infectious diseases, for those who don't know us, including tuberculosis, malaria, lots of major global health problems. We're very supportive of doing that with non-dilutive funding from Gates Foundation and governments and so forth.

Eric EasomCEO

I think the real interest near term is inflection points and value creation in terms of phase II readouts. As I mentioned, we have three proof of concept readouts. All 3 of these, I think, are significant value inflection points for us as a company and really to prove out these compounds. We have multiple shots on goal, if you will. PV being the first of those. Polycythemia vera, we have phase II. We are going to initiate the phase II and have first patient dosed this year. This study is starting imminently. We will have the first kind of safety read of the data in the first quarter, and then throughout 2027, we will have efficacy data. That is an open-label trial, and I will talk a lot more in detail about that.

Eric EasomCEO

This is a once-daily oral red cell targeted therapy for PV, which is a highly sought profile compared to a lot of injectables and off target. Chagas disease too, and I will talk more about this, but we have a potential oral cure for this disease. Currently, the therapy available is not great, and so we really are excited about that. The disease affects 10 million people, 300,000 of which or more live in the U.S. This is a kind of an unknown disease to many people, but 10 million people have parasites in their heart. It is a silent killer, and it is a major health, unaddressed health issue. NTM is Mycobacterium abscessus. This is one where there is, again, like Chagas, there is no FDA-approved drugs for Mycobacterium abscessus. There are 15,000 patients in the U.S., and I will talk more about that.

Eric EasomCEO

We will have data on all 3 of those in 2027. It is lots of data inflection points coming in our near future. Our earlier pipeline, we have three exciting programs, and these will be making further development into clinical trials in late 2027 and forward. A lot more to come on those. All right. We want to spend a lot of time on polycythemia vera. This is a Our compound is epetraborole. It is in phase II, starting imminently, as I mentioned. It is oral, and it is red cell targeting. The real profile, I think, that is highly sought is a once-a-day oral therapy. We have vast amounts of clinical and preclinical data in non-PV patients showing the profile of red cell targeting, hematocrit reduction, which is exactly what you want with this, and selectivity without having lots of off-target activity around that.

Eric EasomCEO

We will have data throughout 2027. This is really the top priority, I think, in the near term for us as a company. Polycythemia vera, this is a disease where there is an overproduction of red blood cells, which leads to kind of a thickening or higher viscosity in your blood and a high risk of thrombotic events for patients with this. The primary treatment for this, you want to keep hematocrit below 45% and keep it in normal. These patients have super high hematocrit, so they have more red blood cells and less room for the cells to flow throughout the body. Currently, the primary treatment is phlebotomies. For a lifetime, you have to get a phlebotomy. In many patients, it is every other month, every month. You can imagine using therapeutic bloodletting essentially as your therapy, and low-dose aspirin to manage platelets.

Eric EasomCEO

There also are cytoreductive agents, but these have lots of off-target activities. They are injectables, other non-desirable features. The idea is to have a red cell targeting oral therapy that does not have a lot of side effects, and that is what we believe we have the potential for and we are going to be testing. I mentioned lots of clinical data. I just highlight one here. This was from a compound that we, this is epetraborole, we studied in a phase II/III nontuberculous mycobacteria lung disease trial. As you can see, our drug on top of an optimized background regimen of multi-antibiotics had a clear effect on hematocrit lowering. It is almost like the perfect step function, if you will.

Eric EasomCEO

It goes down over the first four to eight weeks, then it plateaus, and there is a compensatory action going, and it maintains that, and then as soon as you take drug off, it returns to baseline. This is very reproducible across, we have run more than 10 clinical trials and see the same phenotype, red cell targeting agent. We also see a very well-tolerated profile, and we have seen it in preclinical. We have done lots of NHP studies to also show this and look at PK/PD, et cetera. We have got lots of non-PV data. The real question for us is, will this translate to patients with polycythemia vera? Which we think it will. This just shows kind of the off-target effect. Essentially, it has absolutely no effect on white blood cells and platelets. They stay within normal range and very minor deviations.

Eric EasomCEO

This is unique in the fact that it is oral and does not have that, makes it very red cell specific, which is the exciting part of the profile. In terms of clinical trial, I mentioned we are going to be starting our trial in PV this year. We will be dosing the first patient sometime in the coming weeks, and then we will have a sentinel cohort. There is going to be initial 10 patients at a very low dose in a sentinel, just because we have never dosed a PV patient to see if we see all the right safety features and kind of phenotype, but it is mainly a safety readout, and that will happen in the first quarter.

Eric EasomCEO

That is the planned timeline for when we will read out that, and then they will go straight into this part one, which is all this is open label, so we will be able to see these data in real time. The dose titration will start with a fairly low dose and then allow on a per-patient basis for the dose to be escalated over a long enough period that we can really show the primary purpose of this, which is to reduce the need for therapeutic phlebotomies. That is really exciting. We will start having patients hit the 20-week mark sometime around mid-year, and we will do data cuts. We are not going to wait until we have all 75 to release data. We will have early readouts and then throughout 2027 on that.

Eric EasomCEO

There is a part two, which will then randomize patients off of therapy. We think you will see them go back out of control with phlebotomy only, and then those who stay on drug. That will be a double-blinded. Really, the proof of concept is part one, and that is the major question that we are trying to answer with this. We will be measuring lots of other parameters along the way and give updates on that. Okay, so that is PV. Mycobacterium abscessus. Again, this is no approved therapies by the U.S. FDA for this. Currently, it is all off-label, decades-old antibiotics. There are 15,000 in the U.S., 50,000 if you include Japan and Europe, so major markets here. It is a rare disease that really causes a high five-year mortality. Your lungs become fibrotic. You have a lot of cavities and kind of a fibrosis of the lung, essentially.

Eric EasomCEO

It is a bacteria that is related to Mycobacterium tuberculosis, but quite different and rare. Basically, the treatment for patients now that they have to contemplate is they go on multiple IV-only antibiotics daily for months and years. You can imagine, this is like chemotherapy. They are taking imipenem, they are taking amikacin. These are not for the faint of heart drugs that cause hearing loss, lots of other side effects that make it very demanding for patients to do that on a daily basis. Imagine. It is like old-time chemotherapy, and they take oral antibiotics. That is the situation. What we are really There has not been a lot of focus on this, but we have an oral therapeutic, epetraborole.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day